Related by context. All words. (Click for frequent words.) 57 successfully commercialize 56 Allovectin 7 r 56 regulatory approvals 56 TP# CETi 1 56 requisite regulatory approvals 55 Kayoko Kano acknowledged 55 notlimited 54 Bioenvision compounds under 54 governmental approvals 54 Bioaccelerate compounds under 54 successfully commercialize Iluvien 54 CORLUX CORT # 53 necessary regulatory approvals 53 risks anduncertainties 53 CholeraGarde R Peru 53 lender consents 53 risksassociated 53 ability tosuccessfully 53 Bioenvision dependence 52 Generx TM 52 proprietary Capillary Aerosolization Technology 52 Eligard R 52 Prelude SkinPrep Systems 52 causeactual results 52 regulatory approval 52 affecting Amarin 52 statements arebased 52 ourproducts 52 Thalomid R 52 deploy MDCE services 52 RXi Pharmaceutical Corporation 51 regulatory authorizations 51 ADSI reliance 51 TranSwitch indebtedness 51 viii inability 51 Zemiva TM 51 involverisks 51 proprietary capillary aerosolization 51 risksand uncertainties 51 risks associatedwith 51 incur unanticipated 51 Avivo Corporation 51 vii Cubist ability 50 consummating acquisitions 50 cancellations rescheduling 50 consents authorizations 50 Mediaseed R 50 regarding Heska 50 EPIX Pharmaceuticals 50 stockholder approvals 50 Hiru Corporation ability 50 immunotherapies 2A/Furin 50 Exelbine 50 including withoutlimitation 50 JUVISTA 50 Symphony tCGM 50 aresubject 50 cadence regulatory approvals 50 Shire Attention Deficit 50 EGRIFTA TM 50 OPAXIO pixantrone 50 statementsregarding 50 vii 50 Sular formulation 50 NeoLipid drug 50 regulatory clearances 50 FierceGovernmentIT tracks 50 MAb therapy 50 viii 50 indications Cytokinetics 49 commercialize CorMedix drug 49 Zemiva TM Trofex TM 49 unanticipated difficulties 49 looking statementsare 49 Kosan dependence 49 without limitation 49 successfully commercialize Silenor 49 suchforward looking 49 infringed misappropriated invalid 49 novel proprietary KL4 49 BioSante licensees 49 vaginal lidocaine 49 uncertaintiesthat 49 tivozanib AV 49 Surfaxin LS 49 ourability 49 Shire plc Attention Deficit 49 currentexpectations 49 Mago ® 49 substantial indebtedness 49 otherfactors 49 LPM TM 49 Azedra TM Onalta TM 49 uncertainties 49 Ty# ETEC E. coli 48 Orosi Mill project 48 Immtech clinical trials 48 indebtedness covenant 48 diagnostic radiopharmaceutical 48 PS# Pharmacopeia ability 48 PentaStaph 48 market PolyHeme commercially 48 Symphony tCGM System 48 Somaxon ability 48 involve risksand uncertainties 48 adversely affect Univest Corporation 48 Prelude SkinPrep System 48 IV APAP 48 Discovery Labs 48 Enhance Biotech 48 withrespect 48 anyforward looking 48 Dyax phage display 48 without limitation Terremark 48 AzaSite Xtra 48 ESTRASORB R 48 HYVISC R 48 SURFAXIN 48 bulk amorphous alloys 48 molecular chaperone regulation 48 product introductions 48 Zemiva ™ 48 CompAir acquisition 48 OSI Pharmaceuticals filings 48 CEFF financings subject 48 ELEVESS 48 DRAXIS 48 c SIGA 48 involve risks anduncertainties 48 Cytogen dependence 48 Caliper Driven 48 HealthTronics periodic filings 48 TriPath Oncology 48 LOPROX R 48 Filtran Microcircuits Inc. 48 areas Fertility Transplantation 48 RAPTIVA R 48 TranSwitch filings 48 market fluctuations investee 48 TrueKnowledge Platform TM 48 adversely affecting Cubist 48 orotherwise 48 Alnylam dependence 48 Prospectuses contain 48 Kyowa Kirin 48 novel therapeutic modality 47 satellite datacasting market 47 Auxilium anticipates 47 especially Copaxone ® 47 Captisol ® 47 incorporating FalconStor 47 PharMerica LTC Transaction 47 EVIZON TM squalamine lactate 47 #L Sterilizer 47 StaphVAX R 47 FACTIVE R gemifloxacin 47 differmaterially 47 JZP 6 47 TOCOSOL Paclitaxel 47 VANTAS 47 Neurobionix 47 SILENOR 47 candidate MyVax 47 inherent uncertainty 47 requirements xxii 47 DYNACIN R Tablets 47 assimilating acquired 47 XL# anticancer compounds 47 render PolyHeme obsolete 47 novel L DOS# 47 Heska reliance 47 Candente relies upon 47 InPath TM System 47 STRIANT ® 47 anduncertainties 47 inflammatory autoimmune diseases 47 TRISENOX R 47 oxandrolone USP 47 affect Pennichuck Corporation 47 orBec R 47 ADVENTRX 47 gastrointestinal GVHD include 47 candidate Ramoplanin 47 newproducts 47 Theseforward looking 47 customary regulatory approvals 47 commercialize ZYFLO CR 47 HealthGate ability 47 looking statements.Such 47 subsidiaries visit http:/www.apricusbio.com 47 MONOVISC 47 molecular therapeutics immunotherapies 47 risks associated 47 Ceragenin TM technology 47 treat dysmenorrhea 47 rapid technological advances 47 distinguishing MDCE products 47 HF Lenfest member 47 marketed GeoVax raises 47 Rexahn licensees 47 PerClot 47 suchstatements 47 TIMERx 47 BOPET film industry 47 torsemide ER 47 arenot limited 47 Ondansetron Injection 47 PLIVA dd 47 DeeThree 47 ALN PCS 47 HepeX B 47 CopperGate Emblems 47 acquisitions divestitures mergers 47 OmniComm intends 47 BiDil XR drug 47 please visit www.medicinova.com 47 Rotarix ® 47 dimesylate Attention Deficit 47 repopulate CNS 47 MethyPatch 47 faropenem 47 Cintredekin Besudotox 47 HTDS Corporation 46 Favrille filings 46 TOCOSOL Camptothecin 46 ProUroCare 46 RAPIDGate Program contains 46 materially adversely affect 46 adversely affect Curis 46 Risks uncertainties 46 NitroMed BiDil 46 ultimate recoverability 46 SILENOR ™ 46 Puricase PEG uricase 46 vernakalant oral 46 SynthRx 46 CoTherix logo 46 Plasma Converter TM 46 visit www.targanta.com 46 Pending regulatory approvals 46 Elevess 46 Solazed TM 46 CalciTech products 46 BioGlue ® 46 Yima project 46 theforward looking 46 naronapride 46 InSite reliance 46 novel MetAP 2 46 Receivable purchasing 46 patented Bioral cochleate technology 46 offerings visit www.balqon.com 46 BioGlue R 46 innovative aerosolization 46 develop electroporation 46 Metabasis dependence 46 JM Dutton adds 46 ANDA submission 46 OLIGON technology 46 biomimetics non 46 without limitation Newlook 46 include Altastaph TM 46 subjectto 46 Jinan Fertilizer 46 include ClindaReach TM 46 SANCTURA R 46 SANCTURA SANCTURA XR VANTAS 46 differ materiallyfrom 46 AzaSite Plus 46 candidates Azedra TM 46 adverse determinations 46 inventory obsolescence 46 Somatuline R Autogel R 46 commercialize BiDil 46 Ceragenin ™ technology 46 synthetic nucleic acid 46 BioFX Laboratories 46 Metabasis stockholders 46 research anddevelopment 46 Trofex ™ 46 ADSI cautions 46 developing ostarine selective 46 Tekturna Rasilez 46 collaborations Pharmacopeia 46 estimating quantities 46 Aradigm Logo 46 couldcause actual results 46 factors APPY 46 PLIVA acquisition 46 Nabi HB R 46 Company Skouries Olympias 46 OFIRMEV 46 Prochieve R 46 sells cGMP paclitaxel 46 Phase III LibiGel 46 results ofoperations 46 results performance orachievements 46 Rexahn actual 46 Bioenvision filings 46 Inc. www.transgenomic.com 46 MGCD# MGCD# [002] 46 d SIGA 46 iv 46 Zensana 46 Acetavance TM 46 legal proceedings xxi 46 Orbix R 46 encapsulates siRNAs 46 HydroFix ™ 46 SMA Indústria Química SA 46 AcryMed technologies 46 forward lookingstatements 46 PLAVIX R patent 46 novel ZFP TFs 46 hyperimmune products 46 product platforms AZX# 46 IMA Barytex 46 Crisa acquisition 46 Urokinase 45 economically recoverable coal 45 #L Ozone Sterilizer 45 concerning Epigenomics AG 45 OraTest R 45 These statementsare 45 itsproducts 45 Prodarsan R 45 #CL# 45 plastic photochromic lens 45 InterfeRx TM 45 sNDAs 45 uncertainties inherent 45 biotherapeutic drugs 45 Enpath ability 45 PURPOSE OF SAFE HARBOR 45 commercialize becocalcidiol patented 45 Proposed Transactions 45 Rhucin ® recombinant 45 xvii 45 Form 8K #K 45 ExchangeCommission 45 zileuton IV 45 customary closing conditions 45 mergers dispositions 45 Gestiva TM 45 Prednisporin TM 45 looking statements.These 45 Refinancing Transactions 45 looking statements includingbut 45 ReNvision 45 leading lipid nanoparticle 45 Surfaxin lucinactant 45 limitedto 45 Equinix filings 45 affect Petroflow 45 rheumatoid arthritis thrombocytopenia 45 Lexiscan R 45 Visudyne R 45 xxii 45 Exelixis compounds 45 areforward looking 45 iii Cubist 45 wagering ceasing 45 Lenfest ii 45 Safe Harbors created 45 Atheros Annual Report 45 Mitsue Pipelines 45 nausea vomiting BEMA Granisetron 45 ZEGERID Powder 45 acquisitions mergers dispositions 45 BEMA Granisetron 45 SYCREST 45 Company nanocrystalline materials 45 acquisitions divestures 45 generic Copaxone 45 www.norsat.com 45 Primera Bioscience 45 Linjeta TM 45 PDI periodic filings 45 Corporation PGIC 45 CoStar stent 45 Sulonex TM 45 involve anumber 45 MAA submission 45 markets HP Acthar 45 acquisitions divestitures joint ventures 45 Palatin intends 45 Thrombin topical Recombinant 45 PentaLyte R 45 Rotarix R 45 underwriting discounts commissions 45 Nektar pulmonary 45 filingswith 45 pulls Darvon painkiller 45 xix 45 otherrisks 45 historicalfacts 45 KIACTA TM 45 KRYSTEXXA TM 45 VIOXX Lawsuits 45 KRYSTEXXA TM pegloticase 45 Shire plc filings 45 KRYSTEXXA 45 OrCrude TM process 45 XP# XP# 45 affecting ChinaNet 45 coronary stent merged 45 xi Immtech ability 45 customary closing 45 Staphylococcus aureus Immune Globulin 45 Sepracor anticipates 45 Interpharm 45 Staphylococcus aureus Polysaccharide Conjugate 45 autoimmune indications 45 Chaim Lebovits President 45 commercialization 45 requisite stockholder 45 JOULFERON 45 NeutroTest 45 sumatriptan DosePro 45 e mail lifestyle@readingeagle.com 45 Aloprim TM allopurinol sodium 45 Maruetsu spokeswoman 45 visit www.genmab.com 45 Repros ability 45 sublicense agreements 45 delivery polymer matrix 45 uncertainties materializes FICO 45 Metalink Annual Report 45 concerning Alexza 45 MyVax ® 45 Celacade TM System 45 DPX Survivac 45 commercialize Aganocides 45 Applehead I. 44 regarding Anviron 44 website www.nyandcompany.com 44 PolyHeme successfully 44 Neo Kidney Augment 44 WDEQ Permit 44 AtheroNova filings 44 RECOTHROM ® 44 Dyloject TM 44 International HMIT Announces 44 hoFH 44 APPY believes 44 EHSK 44 Waratah Coal filings 44 affecting IsoTis 44 gastrointestinal disorders ATI 44 Pharmos filings 44 TSX PLB leading 44 Cellegesic 44 Medtronic Annual Report 44 APTIMA HPV assay 44 ThromCat 44 dihydrochloride Phase 3 44 ABRAXANE TM 44 Dyax logo 44 bafetinib 44 polymer platinate 44 Nitram Energy 44 futureperformance 44 TRUSTCASH 44 Telik logo TELINTRA 44 Fortical ® 44 Rosetta dependence 44 general economicconditions 44 Syntroleum Process 44 Atheros Quarterly Report 44 captions Item 1A 44 EOIR insufficient cash 44 futureresults 44 AnorMED expectation 44 Graniz Loan 44 Daytrana TM 44 productdevelopment 44 MultiCell bases 44 ViaCord R 44 DSL.net s 44 AMID Stapler ™ 44 ColonSentry TM test 44 novel anti infective 44 regardingthe 44 contingent guaranties 44 ENABLE Phase 2 44 AirIQ perception 44 Nephros filings 44 Eligard ® 44 visit www.bioject.com 44 candidate Zemiva TM 44 palonosetron hydrochloride Injection Dacogen 44 Sunesis clinical trials 44 involving hydrophilic liquid 44 IoGen 44 Biologic License Application BLA 44 Million Convertible Debt 44 UltiMAb 44 CRINONE R 44 theability 44 patented Bioral 44 Novelis cautions 44 payor acceptance 44 VanceInfo filings 44 RetroMetabolic Drug Design 44 please visit www.rexahn.com 44 Increlex TM 44 TRISENOX ® 44 expressed orimplied 44 ATryn ® 44 NASDAQ EPMD 44 Oracea TM 44 Prednisporin 44 molecular imaging radiopharmaceutical 44 Entereg TM 44 please visit www.middlebrookpharma.com 44 Actiga 44 Company noncontributory defined 44 applicable regulatory approvals 44 Vitaros R 44 affecting BEO Bancorp 44 Thelin tm 44 treat refractory angina 44 Hyperactivity Disorder ADHD 44 San Cristóbal mine 44 consummation 44 histrelin manufacturing marketing 44 should consult NeurogesX 44 Activision Publishing maintains 44 SansRosa 44 pharmacogenomic tests 44 EvaMist NDA submission 44 Tranzeo logo 44 xvi 44 biosurgical 44 Including newbuildings 44 update anyforward looking 44 RECOTHROM R 44 theSecurities 44 Allovectin 7 R 44 Securities andExchange Commission 44 PPG Industries periodic 44 FOLOTYN ® 44 Aphthasol ® 44 Secure Computing periodic 44 STRIANT R 44 intercompany arrangements 44 EHT AGN 44 GEM #S 44 ZALBIN 44 TRIOLEX HE# APOPTONE HE# 44 gastrointestinal mucositis 44 Acticoat TM products 44 adversely affect FNB 44 Salmedix 44 CIP TRAMADOL ER 44 manufacture PolyHeme 44 deducting underwriting 44 involve risks 44 InterDigital differentiated technology 44 Evoltra ® 44 Statement Statements 44 Asentar TM 44 includingstatements regarding 44 Topical Interferon Alpha 2b 44 Bellus Health 44 Submits Biologics License Application 44 minimally dilutive 44 GenVec filings 44 commercialize telaprevir 44 Calixa 44 Immtech scientists 44 cause actual 44 orBec ® oral beclomethasone 44 GELV gasification technology 44 mutually acceptable definitive 44 Assumptions relating 44 novel peptides 44 branded yarns 44 ofnew 44 Hematide ™ peginesatide 44 e# periodic 44 CompanyaEUR TM s 44 economicconditions 44 using Enhanced Chemiluminescence 44 AMEX OTD 44 aerosolized AAT 44 SearchHelp communications 44 molecular immunohematology products 44 oral calcitonin 44 differ materially fromthose 44 VYVANSE TM lisdexamfetamine 44 targeting Inflammatory Bowel 44 Soleus TM software 44 testosterone buccal system 44 DJO Merger 44 RR Donnelley periodic filings 44 mGluR2 mGluR4 mGluR5 mGluR7 44 Research CECR 44 Stimuvax R 44 Soliris TM eculizumab 44 VELCADE therapy 44 xxi 44 Tripos logo 44 GEROVA underwrites insurance 44 novel emulsion formulation 44 nonoccurrence 44 Shire ADHD 44 Paredones Amarillos Project 44 Marbob acquisition 44 looking statements 44 mesylate tablets approved 44 party VLSI fabrication 44 MGCD# MGCD# [001] 44 KIF6 Genotyping Assay 44 unfavorable geologic 44 LandStar Inc. s 43 Amitiza ® 43 Cardica Microcutter ES8 43 Operate Racetrack 43 transthyretin mediated amyloidosis ATTR 43 DIFICID ™ 43 GreenMan Technologies pursues 43 FavId 43 PD2i ® algorithm 43 QUADRAMET R 43 SUPPRELIN LA 43 Azedra ™ 43 include PLX IBD 43 vii IBC 43 palonosetron hydrochloride injection 43 VeraTag assays 43 Visit http:/www.sirona.com 43 product commercializations 43 FalconStor OEM 43 Rexahn 43 Yahoo capitulates 43 â € œwill â 43 develop PS# 43 SurModics Pharmaceuticals 43 Galephar 43 acne impetigo 43 products andservices 43 Toromocho Project 43 NASDAQ PGNX 43 compound CIP FENOFIBRATE 43 faropenem medoxomil 43 TRANSDUR Sufentanil 43 impacting WesBanco 43 DELATESTRYL 43 impair Lillian Vernon 43 Acapodene R 43 IMPDH inhibitor 43 commercialize Hematide 43 Loramyc TM 43 looking statementsâ € 43 Voraxaze 43 UniversalPHOLED 43 tarmac strandings Hanni 43 PAIVIS intends 43 Novartis Wyeth 43 xxiii numerous 43 securityholder approvals 43 CombinatoRx Annual Report 43 concerning Xanthus 43 APDN SEC 43 GLASSIA 43 Scivanta Medical Corporation 43 ChemoNeutralizers 43 Cephalon GlaxoSmithKline Organon 43 AcryMed Incorporated 43 Orphan Drug designations 43 Azixa ™ 43 mGluR4 mGluR2 43 PROVISIONS OF THE PRIVATE 43 TSX Venture AHR 43 securities issuable pursuant 43 theseforward looking 43 Bionutrics 43 http:/www.appliedbiosystems.com 43 SILENOR TM 43 NeoMagic circle 43 RPTN common 43 Rami Efrati CEO 43 HuMax TAC 43 http:/www.masimo.com 43 Tyzeka Sebivo 43 SUPPRELIN LA DELATESTRYL 43 AzaSite TM 43 OneBeacon filings 43 Nicotine Conjugate Vaccine 43 Nasdaq NPSP announced 43 maycause 43 innovative signaling pathway 43 thoseexpressed 43 pentadentate logo R 43 Cardium Therapeutics TM 43 Fortical R 43 vinorelbine emulsion 43 HemoStase 43 MDVIP collects 43 forward.looking statements 43 periodic reports 43 www.sensio.tv 43 Medicis Inamed 43 NASDAQ PHRM 43 commercializing Mirel 43 GTC recombinant human 43 projections anticipations 43 reflect Ronn Motor 43 BLA filing 43 HOLDRS SM 43 ZEGERID Capsules 43 Neurogen stockholders 43 Nabi HB Intravenous 43 NYMET Holdings 43 vaginally administered lidocaine 43 commercialization milestones 43 beyond Forent 43 infringement invalidity 43 Cytokinetics specified 43 andgeneral 43 omission interruption deletion defect 43 GVAX cancer 43 P#X# antagonist 43 Gujiao facility 43 Nycomed GmbH 43 Entereg R 43 escalation unavailability 43 commercialize NicVAX 43 BiDil XR 43 Voxware filings 43 CFRA forensic accounting 43 regulatory 43 AudioCodes filings 43 ZENNergy TM drivetrain 43 technological innovations adversely affecting 43 offuture 43 TSX PWE FRANKFURT 43 Nellix 43 Pixelplus cautions readers 43 InterfeRx 43 blood thinner rivaroxaban 43 ACLARA 43 Duromist 43 nephropathic cystinosis 43 please visit www.mscsoftware.com 43 Vanda inability 43 developments affecting SIAF 43 BOPET film 43 Aphthasol R 43 MedCom USA Inc. 43 SeraCare competitors 43 MOSAID litigation 43 NASDAQ CVV 43 hide reddened eyes 43 xiii 43 Optimer filings 43 LE SN# 43 IFS 2C 43 Civacir 43 NxStage anticipates 43 aldehyde dehydrogenase ALDH2 deficiency 43 PER.C6 r 43 ix 43 ATryn R 43 futureevents 43 CAUTIONARY STATEMENT Statements 43 i Immtech 43 ADVEXIN clinical 43 Omigard 43 Company periodic filings 43 Yucheng filings 43 JHP Pharmaceuticals LLC 43 LEP ETU 43 ArQule Kinase Inhibitor 43 concerning Sparton 43 ourbusiness 43 Brokered Financing 43 visit www.adm.com 43 Bioral Amphotericin B. 43 xxiii 43 operating subsidiary TradeStation 43 Gaoan facility 43 symbol WGNB 43 developing chemokine 43 Resverlogix Corp. 43 non personalized allogeneic 43 proprietary intranasal insulin 43 Hiru Corporation 43 BioForce Nanosciences actual 43 AnGes 43 topical dermatology 43 please visit http:/www.toshiba.com/taec/ 43 noticeably thinner stark 43 commercialize Aganocide compounds 43 affect NYMET Holdings 43 Monovisc 43 histamine dihydrochloride 43 TSX OBP 43 Terremark filings 43 Ibis T# TM 43 Amylin Lilly 43 OMNI dependence 43 Tradient Technologies Inc. 43 Lasertel subsidiary 43 MTI MTI Micro 43 low TSNA tobacco 43 bioMETRX filings 43 vernakalant iv 43 http:/www.optimerpharma.com 43 Neurokine 43 maydiffer materially 43 x Immtech 43 OraTest 43 iii 43 permitting timelines 43 Emisphere filings 43 Sleeping Giant mines 43 Xechem Nigeria 43 SonoPrep device 43 Immunicon dependence 43 3f Therapeutics 43 HepaGam B R 43 AtriCure Isolator ® 43 ii Immtech ability 43 CLX Investments 43 VIBATIV ™ 43 JunJing III 43 TSX VENTURE GAP 43 incorporate proprietary Microvolt 43 GenVec cautions 43 DCVax R Prostate 43 Dynepo TM 43 CorePharma LLC 43 Flutiform TM 43 permits consents 43 EpiCept NP 1 43 TRANSDUR ® 43 difficulties foreseeing 43 OMAPRO ™ 43 R isosorbide dinitrate 43 DC Bead 43 proprietary Vitoss TM 43 TaiGen 43 actualresults 43 Furthermore ArQule 43 relocation visit www.ohiomeansbusiness.com 43 Miikana 43 ELADUR TM 42 Lebowa transaction 42 Ascend Therapeutics 42 Wyeth Torisel 42 Flutiform ™ 42 Neuro Hitech 42 NovaDel oral spray 42 NanoCrystal technology 42 theavailability 42 cosmetic cosmeceutical products 42 orthobiologic 42 includes iFinix RealTime 42 area Longueuil Dorval 42 signal averaging electrocardiography 42 TSX VENTURE BRI 42 LensAR Laser System 42 Paredones Amarillos gold 42 Immunotherapeutic 42 Announce Shareholder Approval 42 BioGold Fuels 42 Subscription Receipt Offering 42 cerebral oximeter available 42 Ceplene ® 42 itssubsidiaries 42 IL# PE#QQR 42 Laurion cautions against 42 Pure Biofuels ability 42 Compans 42 BREAKYL 42 asset monetizations 42 Nellix technology 42 ™ testosterone gel 42 5 lipoxygenase inhibitor 42 OMNARIS HFA 42 Cellceutix actual 42 targets TRPM8 42 Hejia Software 42 miconazole MBT 42 VaxGen stockholders 42 uncertainties materialize Shire plc 42 Combidex 42 Icefloe 42 TNRO 42 cause actualresults 42 PrivateSecurities Litigation Reform Act 42 mutually satisfactory definitive 42 constituteforward looking 42 Adnectin 42 Lovaza TM 42 websites www.industrial nanotech.com 42 TM Acetavance TM 42 Fibrocaps 42 USP Tablets PEPCID 42 Taiho Pharmaceutical 42 Perihelion Global focuses 42 carbonate Direct FuelCell 42 tantalum lithium tin 42 INTEGRILIN ® 42 PER.C6 ® production 42 eastern Denver Julesburg 42 reflect iSIGN Media 42 Enlarged Group 42 Convera filings 42 Kakanda Project 42 Urocidin TM 42 Proprius Pharmaceuticals 42 disinterested Shareholder approval 42 SILCRYST TM coatings 42 party payor reimbursement 42 ESTRASORB ® 42 reflect GuestLogix 42 AMITIZA lubiprostone 42 lucinactant 42 baggage misconnections 42 prescription brands RESTYLANE 42 Idenix anticipates 42 R DYNACIN R 42 Synvista Therapeutics filings 42 cyclical downturns affecting 42 egX Canada 42 Onalta ™ 42 EPRI conducts 42 PDTI 42 Syntonix 42 PharmaBio 42 Virgo Rahu 42 factor factor VIIa 42 CRINONE ® 42 candidate XP# 42 Genaera filings 42 Company Nasdaq RGDX 42 Naglazyme R 42 Cutanea 42 affecting mortality morbidity 42 commercialized DURECT 42 Allegra ® 42 Closes Oversubscribed 42 developed PokerPro automated 42 Cellu Tissue stockholders 42 Thalomid ® 42 valtorcitabine 42 Novavax filings 42 TSX VENTURE PPY.A TSX 42 Additionally Soligenix 42 EGRIFTA ™ 42 subsidiaries Cantronic 42 Insegia 42 PETER PASSI covers 42 Lumenis invests heavily 42 intents beliefs 42 M Enoxaparin 42 PLAVIX ® 42 OTC Bulletin Board TENF 42 commercialize Qutenza 42 http:/www.nansulate.com 42 forward lookinginformation 42 include sutures needles 42 successfully commercialized 42 Aclasta Reclast 42 Novavax cautions 42 ONSOLIS 42 ZFNs clinical trials 42 Trubion stockholders 42 generation vaginal progesterone 42 www.TheNewATT.com 42 Hiru Corporation estimate 42 CAUTIONARY STATEMENT Estimates 42 Nortel strategic alliances 42 proprietary Isolagen Process 42 Cautionary Disclosures 42 micellar nanoparticle MNP 42 Guinea Alumina Refinery 42 follows Obagi Nu 42 Omigard TM 42 Commissions trailing 42 Blitz Weinhard Brewing 42 Dyax utilizes 42 line periodically spurted 42 Submits Response 42 Lignol files 42 Valera Pharmaceuticals Inc. 42 Isolagen specializes 42 Financing Condition 42 Agria beliefs 42 enoxaparin sodium injection 42 cMET inhibitor 42 INTEGRILIN R eptifibatide Injection 42 highly purified pasteurized 42 CRINONE ® 8 42 pretzels sandwich crackers 42 Evader Inc.